title: Hormonal therapy after stem cell transplantation and risk of veno-occlusive disease.
authors.forename: S
authors.initials: S
authors.lastname: Sica
authors.forename: P
authors.initials: P
authors.lastname: Salutari
authors.forename: P
authors.initials: P
authors.lastname: Chiusolo
authors.forename: S
authors.initials: S
authors.lastname: Cicconi
authors.forename: F
authors.initials: F
authors.lastname: Sorá
authors.forename: L
authors.initials: L
authors.lastname: Laurenti
authors.forename: N
authors.initials: N
authors.lastname: Piccirillo
authors.forename: P
authors.initials: P
authors.lastname: Scirpa
authors.forename: G
authors.initials: G
authors.lastname: Leone
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D020249:Hormone Replacement Therapy; D006801:Humans; D007938:Leukemia / Q000628:therapy; D016729:Leuprolide / Q000627:therapeutic use*; D008223:Lymphoma / Q000628:therapy; D008875:Middle Aged; D017697:Premenopause; D012307:Risk Factors; D014592:Uterine Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D014652:Vascular Diseases / Q000517:prevention & control*
chemical_list: D016729:Leuprolide